15. Segment Reporting

The Company has one reportable segment which focuses on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. The Company’s CODM, the CEO, manages the Company’s operations on a consolidated basis as one operating segment for the purposes of evaluating financial performance and allocating resources.

The Company has not generated any revenue yet. The CODM assesses the financial performance of the segment and decides how to allocate resources based on net loss on a consolidated basis. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.

The CODM uses net loss predominantly in the annual operating budget and in the strategic planning and forecasting process. Such loss measure is used to monitor budget versus actual results on an ongoing basis by the

CODM and determine how resources are allocated to the various activities of the Company. The CODM also uses net loss to evaluate the Company’s performance and assist in determination of management’s incentive compensation.

All of the Company’s tangible assets are held in the United States. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

The table below is a summary of the segment loss, including significant segment expenses:

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

Revenues

 

$

 

 

$

 

Research and development expenses:

 

 

 

 

 

 

LTI-01 program-related expenses:

 

 

 

 

 

 

Preclinical study costs

 

 

2

 

 

 

 

CMC activities

 

 

3,566

 

 

 

57

 

Clinical operation activities

 

 

46

 

 

 

28

 

Total LTI-01 program-related expenses

 

 

3,614

 

 

 

85

 

LTI-03 program-related expenses:

 

 

 

 

 

 

Preclinical study costs

 

 

1,935

 

 

 

383

 

CMC activities

 

 

2,451

 

 

 

214

 

Clinical operation activities

 

 

3,913

 

 

 

771

 

Total LTI-03 program-related expenses

 

 

8,299

 

 

 

1,368

 

Other program-related expenses

 

 

54

 

 

 

953

 

Employee related expenses

 

 

2,200

 

 

 

1,214

 

Professional fees for services

 

 

34

 

 

 

324

 

Facilities and other expenses

 

 

47

 

 

 

47

 

Total research and development expenses

 

 

14,248

 

 

 

3,991

 

General and administrative expenses:

 

 

 

 

 

 

Employee related expenses

 

 

5,465

 

 

 

2,723

 

Professional fees for services

 

 

6,257

 

 

 

7,053

 

Facilities and other expenses

 

 

2,142

 

 

 

1,581

 

Total general and administrative expenses

 

 

13,864

 

 

 

11,357

 

Impairment loss on intangible assets

 

 

37,000

 

 

 

 

Restructuring and other costs

 

 

 

 

 

928

 

Other income, net

 

 

(685

)

 

 

(544

)

Income tax benefit

 

 

(1,544

)

 

 

 

Segment and consolidated net loss

 

$

(62,883

)

 

$

(15,732

)

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.